Navigation Links
Pharmos Corporation Reports 2009 First Quarter Results
Date:5/12/2009

to $147,157 in other expense in 2009. The majority of the decrease is from decreased interest income of $125,413 from a decline in cash, cash equivalents and short term investments. We also recorded a $30,685 translation loss on assets held in Israel due to currency translation fluctuations. In the first quarter of 2009 the Company recorded $119,838 in interest expense related to the issuance of $4,000,000 in convertible debentures issued on January 3, 2008.

About Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders. The Company's only product in development, dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders. These are available for licensing / partnering. On February 18, 2009, Pharmos Corporation and its Israeli subsidiary, Pharmos Ltd., entered into an Asset Purchase Agreement with Reperio Pharmaceuticals Ltd. for the sale of the patent rights and technical know-how related to the compound known as PRS-639,058 and certain follow-on molecules.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market pe
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pharmos Completes Private Placement - Raises $1.8 Million
2. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
3. Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
4. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
5. Pharmos Corporation Reports 2008 Third Quarter Results
6. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
7. Pharmos Restructures Operations in Israel
8. Volcano Corporation Presentation at JMP Conference to be Webcast
9. Medical Care Corporation Enables Early Detection of Memory Loss Due to Alzheimers Disease
10. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
11. Former Executive Director of the World Bank and CEO of OMERS Nominated as Directors for Biovail Corporations Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2014)... (PRWEB) December 20, 2014 Dress company LunaDress ... dresses, and announced its Christmas Sale, offering big discounts on ... “Every girl has an idea to own a perfect wedding ... for your wedding dress, then come to LunaDress. Many different ... for you. Visit our website now and enjoy the current ...
(Date:12/20/2014)... 20, 2014 Recently, VogueQueen.com, a leading ... VogueQueen Big Sale Online for 2015. Great discounts ... new and old consumers can get a discount, up ... the company’s website before January 30, 2015. , VogueQueen.com ... and launched a prom dress promotion. Many customers worldwide ...
(Date:12/20/2014)... Francisco, CA (PRWEB) December 20, 2014 ... Social Innovation company just launched first birthday focused portal ... services, “MERRY BIRTHDAY MESSAGE” launched in both US and ... MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY ... for everyone’s birthday around the world. , Features, Choose ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men and ... other serious side effects will be consolidated in the ... pretrial proceedings, Wright & Schulte LLC reports. The U.S. ... Friday to transfer 21 Xarelto lawsuits and over 30 ... the Louisiana district court for coordination by Judge Eldon ...
(Date:12/19/2014)... Today, Balfleet.com , a leading ... its formal dress promotion. All the old and new ... off. , Balfleet.com is well-known for its high quality ... dresses, cocktail dresses and more. Its formal dresses are ... and they can create an elegant look when paired ...
Breaking Medicine News(10 mins):Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2
... initiated a worldwide recall on October 19, ... having Catalogue No.,10012-2555-001, serial numbers 488 or ... The current Instructions for Use state that,IVADs ... position or placed,in the paracorporeal (external) position. ...
... Various Shades of Colored Contact ... ... look with a new eye color? ACUVUE 2 COLOURS now,offers iMakeover(TM), a ... eye color a sneak peek of,what they would look like with different ...
... Revenue Increases 12%; Fully-Diluted EPS Increases to $0.89 per ... ... Methods Corporation,(Nasdaq: AIRM ) reported results for the quarter ended September ... year-ago,quarter. For the nine-month period, revenue increased 13% to $273.7,million, up from ...
... AG,a biopharmaceutical company developing Anticalins(R), a novel class ... of Dr,Angelika Stern as Chief Operating Officer to ... immediate effect of Dr Andreas Hohlbaum from,the position ... Chief,Technology Officer. The appointment of Dr Angelika ...
... Cell Therapeutics, Inc. (CTI),(Nasdaq and MTAX: CTIC) today reported recent ... September 30, 2007. Recent Events, -- Announced agreement ... first FDA-approved radioimmunotherapy, from Biogen Idec; this ... group of only a few biotech ...
... Industry Thought Leader Joins Healthcare ... Management Consulting Practice, SANTA ... announce the appointment of Ogan Gurel, M.D. as a Managing,Director ... Dr. Gurel join our team," said Vip Jain - Principal ...
Cached Medicine News:Health News:URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device 2Health News:ACUVUE(R) 2 COLOURS(R) Brand Contact Lenses Launches Virtual Eye Makeover Tool 2Health News:ACUVUE(R) 2 COLOURS(R) Brand Contact Lenses Launches Virtual Eye Makeover Tool 3Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 2Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 3Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 4Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 5Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 6Health News:Air Methods Reports 3Q2007 Results and 4Q2007 Update 7Health News:Pieris Strengthens its Management, as it Prepares for the Clinical Development of PRS-050, an Anticalin(R)-Based Novel Cancer Therapy 2Health News:Pieris Strengthens its Management, as it Prepares for the Clinical Development of PRS-050, an Anticalin(R)-Based Novel Cancer Therapy 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 4Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 5Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 6Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 7Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results 8Health News:XRoads Solutions Group Appoints Dr. Ogan Gurel as Managing Director 2
(Date:12/19/2014)... separating membrane market has witnessed robust development with the ... as a later starter. In 2012, the size of ... billion, with the proportion worldwide soaring to 16.3%. It is ... will continue its growth rate by around 20% in the ... to roughly RMB25 billion. An integrated membrane industrial ...
(Date:12/17/2014)... HOLBROOK, N.Y. , Dec. 17, 2014 /PRNewswire/ ... that The Depository Trust Company (DTC) has made ... the Deposit Chill on the Company,s stock effective ... of Northstar,s common stock for depository and book ... and the Company is now once again fully ...
(Date:12/17/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or the ... $125 million aggregate principal amount of 3.75% Convertible Senior ... and sold only to qualified institutional buyers pursuant to ... amended (the "Securities Act"). The Notes bear ... payable semiannually in arrears on June 15 and December ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... Sciences University, Augusta, GA  exhibited a poster ... Research in Los Angeles, in which their clinical study ... IV Connector significantly decreased the incidence of catheter-related ... to a simple split septum with negative displacement IV ...
... Food and Drug Administration is warning that terbutaline administered by ... in pregnant women for prevention or prolonged (beyond 48-72 hours) ... maternal heart problems and death. In addition, oral terbutaline tablets ... labor. The FDA is requiring the addition of a Boxed ...
Cached Medicine Technology:New Clinical Study Shows RyMed InVision-Plus® IV Connector Dramatically Reduced Catheter-Related Bloodstream Infections by Over 92% 2New Clinical Study Shows RyMed InVision-Plus® IV Connector Dramatically Reduced Catheter-Related Bloodstream Infections by Over 92% 3FDA Warns Against Certain Uses of Asthma Drug Terbutaline for Preterm Labor 2FDA Warns Against Certain Uses of Asthma Drug Terbutaline for Preterm Labor 3
Sterile Silicone Oil for Intraocular Application....
Round knurled handle, overall length 130 mm....
Optimum C/D/S Solution is a sterile cleaning, disinfecting, and storage solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and hard contact lenses....
Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
Medicine Products: